Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Trial ID or NCT#
Status
Purpose
To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
Official Title
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Eligibility Criteria
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Phuong Pham
650-725-9810
View on ClinicalTrials.gov